Atossa Genetics
Price & Volume
Stats
See more52W Range | $0.55-$1.81 |
Market Cap | $83.4M |
Shares Short | 8M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$0.20 |
News
See moreYahoo Finance • 25 days ago
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Yahoo Finance • last month
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
Yahoo Finance • 2 months ago
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
Yahoo Finance • 3 months ago
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025
About
CEO | Dr. Steven C. Quay FCAP, M.D., Ph.D. |
Address | 107 Spring Street, Seattle, WA, United States, 98104 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 15 |
